A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion

Guardado en:

Detalles Bibliográficos
Autor principal:	Masatoshi Kudo
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	hepatocellular carcinoma intermediate-stage hepatocellular carcinoma atezolizumab/bevacizumab curative conversion Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3b527f3351db4053af3b26a90b2bfcec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3b527f3351db4053af3b26a90b2bfcec
record_format	dspace
spelling	oai:doaj.org-article:3b527f3351db4053af3b26a90b2bfcec2021-11-11T10:40:45ZA Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion2235-17951664-555310.1159/000519749https://doaj.org/article/3b527f3351db4053af3b26a90b2bfcec2021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/519749https://doaj.org/toc/2235-1795https://doaj.org/toc/1664-5553Masatoshi KudoKarger Publishersarticlehepatocellular carcinomaintermediate-stage hepatocellular carcinomaatezolizumab/bevacizumab curative conversionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLiver Cancer, Vol 10, Iss 6, Pp 539-544 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma intermediate-stage hepatocellular carcinoma atezolizumab/bevacizumab curative conversion Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hepatocellular carcinoma intermediate-stage hepatocellular carcinoma atezolizumab/bevacizumab curative conversion Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Masatoshi Kudo A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
format	article
author	Masatoshi Kudo
author_facet	Masatoshi Kudo
author_sort	Masatoshi Kudo
title	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
title_short	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
title_full	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
title_fullStr	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
title_full_unstemmed	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
title_sort	novel treatment strategy for patients with intermediate-stage hcc who are not suitable for tace: upfront systemic therapy followed by curative conversion
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/3b527f3351db4053af3b26a90b2bfcec
work_keys_str_mv	AT masatoshikudo anoveltreatmentstrategyforpatientswithintermediatestagehccwhoarenotsuitablefortaceupfrontsystemictherapyfollowedbycurativeconversion AT masatoshikudo noveltreatmentstrategyforpatientswithintermediatestagehccwhoarenotsuitablefortaceupfrontsystemictherapyfollowedbycurativeconversion
_version_	1718439115481939968

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion

Ejemplares similares